Seventy-three high-risk neuroblastoma patients (stage M at age > 18 months or MYCN-amplified stage L1/L2 at any age) were given N7-based chemotherapy regimens followed by naxitamab and subcutaneous GM-CSF. Here, CSF2 is linked to neuroblastoma.